Clinical Trial Search

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 8.5; 36.1; 36.4…

Primary: Maximum Observed Concentration (Cmax) — 884.297; 963.384; 942.653 Nanograms per milliliter (ng/mL) — p=0.1413

Primary: Mean Change From Baseline in Muscle Function Using the 6 Minute Walking Distance — -10.98; -19.93; 16.12 Meters — p=0.554

Primary: Nocturnal Blood Pressure — 128.2; 124.7; 70.6; 68.8 mmHg — p=0.45

Primary: Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36) — -1.156; -0.765; 0.002; 0.781 Score on a scale

Primary: Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC) — 1.01; 1.63; 1.29; .73 mV

Primary: Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in…

Primary: Maximal Decrease From Baseline in log10 HCV RNA Levels During ABT-493 or ABT-530 Monotherapy Treatment — -4.11; -4.02; -4.31; -4.06 Log10 IU/mL

Primary: Change From Baseline Three Item Severity (TIS) Scores Between GW870086 (0.2% and 2%) Versus Placebo at Day 22 — -1.99; -2.49; -1.61; -3.11 Score on scale — p=0.480

Primary: LSAS-performance Subscale — 34.04; 32.54; 32.05 units on a scale

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.1 percentage of participants

Primary: PFS — 4; 1 Participants

Primary: Mean Number of Doses of HBV Vaccine Received — .78; .85; .94; .98 Doses of HBV Vaccine — p==.885

Primary: Cumulative Narcotic Consumption — 19; 14 Participants

Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants